Novavax Reports $1.1 Billion Revenue and $440.3 Million Net Income for Fiscal Year 2025

Novavax, Inc. reported significant financial performance improvements for the fiscal year ending December 31, 2025, with total revenue reaching $1.1 billion, a substantial increase of $441.3 million compared to $682.2 million in 2024. This growth was primarily driven by product sales, particularly from the termination of advance purchase agreements (APAs) with Canada and New Zealand, which contributed $575.7 million and $27.3 million, respectively. Product sales specifically from the COVID-19 vaccine, Nuvaxovid, amounted to $685.0 million, up from $213.2 million in the previous year. However, licensing, royalties, and other revenue decreased to $438.4 million from $469.0 million, largely due to reduced revenue from the Sanofi collaboration.

The company experienced a net income of $440.3 million in 2025, a significant turnaround from a net loss of $187.5 million in 2024. This improvement was attributed to increased revenues and a reduction in total expenses, which fell to $670.7 million from $931.1 million in the prior year. The decrease in expenses was driven by cost containment measures, including a reduction in the global workforce and the sale of the Novavax CZ manufacturing facility. The company also recognized a $97.8 million impairment loss related to assets held for sale during the year.

Strategically, Novavax has made notable advancements in its partnerships and product pipeline. In January 2026, the company entered into a license agreement with Pfizer for the use of its Matrix-M™ adjuvant, which includes an upfront payment of $30 million and potential milestone payments totaling up to $500 million. The collaboration with Sanofi also continued to yield results, with $225 million in milestone payments earned in 2025. Additionally, Novavax is advancing its early-stage vaccine candidates, including those targeting Clostridioides difficile and shingles, and plans to enter clinical trials for at least one program by 2027.

Operationally, Novavax reported a workforce of approximately 749 employees as of December 31, 2025, reflecting ongoing restructuring efforts. The company is also focused on expanding its geographic reach and product adoption, with the R21/Matrix-M™ malaria vaccine achieving over 80% market share in several countries since its launch. However, the company faces challenges, including reliance on third-party manufacturers for vaccine production and potential delays in clinical trials due to various factors, including regulatory approvals and market conditions.

Looking ahead, Novavax's outlook remains cautious as it continues to navigate the complexities of vaccine development and commercialization. The company anticipates ongoing losses as it invests in research and development, particularly for its COVID-19 vaccine and other candidates. The ability to secure additional funding and successfully execute its business development initiatives will be critical for sustaining operations and achieving long-term profitability.